Status: Recruiting
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Participants needed: 53
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Kuirong JiangUpdated: Apr 11, 2024Locations: 1
Eligibility criteria
ECOG performance status 0 or 1. [+4]
Patients who cannot eat orally and have gastric emptying disorder after surgery; [+3]